For the quarter ending 2025-09-30, SAVA had -$6,301K decrease in cash & cash equivalents over the period. -$6,301K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -10,807 | -67,627 |
| Stock-based compensation | 4,402 | 9,806 |
| Gain from change in fair value of warrant liabilities | 0 | 0 |
| Depreciation and amortization | 131 | 438 |
| Prepaid and other current assets | 390 | -5,518 |
| Accounts payable and accrued expenses | 2,959 | 35,168 |
| Accrued development expense | -2,422 | 1,348 |
| Accrued compensation and benefits | -201 | -794 |
| Other liabilities | 107 | -140 |
| Net cash used in operating activities | -6,221 | -16,283 |
| Purchases of property and equipment | 80 | 0 |
| Net cash used in investing activities | -80 | 0 |
| Proceeds from exercise of common stock warrants, net of exercise costs | 0 | 0 |
| Proceeds from issuance of common stock upon exercise of stock options | 0 | 90 |
| Net cash provided by financing activities | 0 | 90 |
| Net increase (decrease) in cash and cash equivalents | -6,301 | -16,193 |
| Cash and cash equivalents at beginning of period | 128,574 | - |
| Cash and cash equivalents at end of period | 106,080 | - |
CASSAVA SCIENCES INC (SAVA)
CASSAVA SCIENCES INC (SAVA)